Case study reveals enhanced detection of metastatic sites using Trivehexin PET in breast cancer patients, indicating improved imaging potential.
FDG PET CT has limitations in breast cancer due to its low tracer uptake in Grade 1 and 2 tumors, estrogen receptor positivity, lobular histology, and osteoblastic skeletal metastases. Trivehexin PET targets αvβ6 integrin, which is relatively specific for epithelial cancer cells. We present a case of a 67-year-old woman with recently diagnosed metastatic breast cancer. Trivehexin PET not only showed lesions with a higher target-to-background ratio compared with FDG PET but also depicted additional metastatic sites.
No takes yet. Share an insight, caveat, or question.
Mohite et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: